Regeneron Pharmaceuticals · US75886F1075 · REGN | XNAS | Prime AI Terminal

CUSIP

75886F107

SEDOL

2730190

CIK

0000872589

www.regeneron.com

LEI: 549300RCBFWIRX3HYQ56

New: Infographics X-Lab

Regeneron Pharmaceuticals Inc

BASIC = Free ADVANCED = User Account BUSINESS = Subscription PRIME = Subscription

ENTERPRISE = upon request

PROFILER

BASIC

ADVANCED

BUSINESS

PRIME

AI Insights

Regeneron Pharmaceuticals

Click to initiate

ENTERPRISE

6.488,67 S&P · 15,58 Vola-Index · 119.231,50 BTC · 1,16713 EURUSD

Here you will find information from the operators of the Frankfurt and XETRA stock exchanges relating to the selected company. You will find announcements and executions of corporate actions, dividend distributions, trading interruptions and much more. This link will take you to the complete overview of all stock exchange announcements.

Thu, 14.08.2025

Das Instrument RGO US75886F1075 REGENERON PHARMAC.DL-,001 EQUITY wird cum Dividende/Zinsen gehandelt am 15.08.2025 und ex Dividende/Zinsen am 18.08.2025 The instrument RGO US75886F1075 REGENERON PHARMAC.DL-,001 EQUITY has its pre-dividend/interest day on 15.08.2025 and its ex-dividend/interest day on 18.08.2025

Research & Analysis

#XFRA #DIVIDEND

Tue, 18.02.2025

Das Instrument RGO US75886F1075 REGENERON PHARMAC.DL-,001 EQUITY wird cum Dividende/Zinsen gehandelt am 19.02.2025 und ex Dividende/Zinsen am 20.02.2025 The instrument RGO US75886F1075 REGENERON PHARMAC.DL-,001 EQUITY has its pre-dividend/interest day on 19.02.2025 and its ex-dividend/interest day on 20.02.2025

Research & Analysis

#XFRA #DIVIDEND

We are different

OPEN FINANCIAL

DATA & KNOWLEDGE HUB

We make the difference

Information on product placements

BARRISTA SMART * AD

P R O D U C T S U G G E S T I O N S

Subject *

i.e Feature x is not working

Issue happened on *

This page

Other page

Page URL

Paste the page URL here

Bug Detail *

Please give us more detailed explanation of the issue

Steps to reproduce *

Specify the steps you've done before the issue happen

Actual Result *

What's the result of the issue?

Expected Result *

What do you expect to see?

Attachment

(Optional) You can send us a screenshot, word document, or a PDF explaining the issue

You have pressed the "". We would like to inform you that you are now leaving the information service of the portal site ayondo.com. You will be redirected to . After confirming the "Continue" button, you confirm that you have been informed of this. You also confirm that you are carrying out this process of your own free will and that it is not the result of any promotional activity or other influence. Continue to .

I would like to remain anonymous.

Subject *

e.g. New calculation method for Risk-of-Ruin-Calculator

View/Tool *

This view/tool

Another page/tool

Description of the proposed change/feedback *

The more comprehensible the description, the faster a feasibility check can be carried out.

General feedback on the view/tool/component/content *

Use this feedback text field for general or supplementary information

Would you use the tool and recommend it if necessary? *

Your opinion is valuable. Feel free to share it with us.

Regeneron Pharmaceuticals Inc

XFRA: DIVIDEND/INTEREST INFORMATION - 18.08.2025 - US75886F1075

XFRA : DIVIDEND/INTEREST INFORMATION - 20.02.2025 - US75886F1075

Newsletter